![Study Results & Research Projects Study Results & Research Projects](https://webarchive.library.unt.edu/eot2008/20090116154134im_/http://ntp-server.niehs.nih.gov/images/template/subMastHead_studyResults.gif)
Summaries & Associations of Study Results
Summaries & Associations of Study Results
Home » Study Results & Research Projects » Summaries & Associations of Study Results » TR-467 Chloroprene
CHEMICAL/ CAS NUMBER | PEER REVIEW DATE | PRIMARY USES | ROUTE/EXPOSURE LEVELS | STUDY LABORATORY |
---|---|---|---|---|
CHLOROPRENE 126-99-8 |
12/11/96 | MONOMER FOR NEOPRENE ELASTOMERS. INDUSTRIAL RUBBER PRODUCTS. COMPONENT OF ADHESIVES IN FOOD PACKAGING. (TDB) | Inhalation R&M: 0, 12.8, 32.0, OR 80.0 PPM; 50/SEX/SPECIES/GROUP | Battelle Northwest Laboratory |
LEVELS OF EVIDENCE OF CARCINOGENICITY--ORGAN/TISSUE (NEOPLASM): | ||||
MR: CLEAR EVIDENCE | ORAL CAVITY: SQUAMOUS CELL PAPILLOMA 0/50 2/50 4/50 10/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 2/50 COMBINED 0/50 2/50 5/50 12/50 | |||
THYROID GLAND FOLLICULAR CELL: ADENOMA 0/50 2/50 2/49 4/50 OR CARCINOMA 0/50 0/50 2/49 1/50 COMBINED 0/50 2/50 4/49 5/50 | ||||
LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA 2/50 0/50 3/49 3/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/50 2/50 1/49 4/50 COMBINED 2/50 2/50 4/49 6/50 | ||||
KIDNEY TUBULAR CELL: (SINGLE SECTIONS) ADENOMA 0/50 1/50 1/50 2/50 (SINGLE AND STEP SECTIONS) ADENOMA 1/50 7/50 6/50 7/50 OR CARCINOMA 0/50 2/50 0/50 1/50 COMBINED 1/50 9/50 6/50 8/50 | ||||
MAY HAVE BEEN RELATED: | URINARY BLADDER: TRANSITIONAL EPITHELIUM PAPILLOMA 0/50 0/50 0/50 1/49 OR CARCINOMA 0/50 0/50 1/50 0/49 | |||
NON-NEOPLASTIC LESIONS: | LUNG: ALVEOLAR EPITHELIUM HYPERPLASIA | |||
KIDNEY: INCREASED SEVERITY OF NEPHROPATHY | ||||
NASAL CAVITY: (OLFACTORY EPITHELIUM) ATROPHY; FIBROSIS; HYPERPLASIA; CHRONIC INFLAMMATION; METAPLASIA; NECROSIS | ||||
FR: CLEAR EVIDENCE | ORAL CAVITY: SQUAMOUS CELL PAPILLOMA 1/49 2/50 2/50 7/50 OR SQUAMOUS CELL CARCINOMA 0/49 1/50 3/50 4/50 COMBINED 1/49 3/50 5/50 11/50 | |||
THYROID GLAND FOLLICULAR CELL: ADENOMA 1/49 1/50 0/50 3/50 OR CARCINOMA 0/49 0/50 1/50 2/50 COMBINED 1/49 1/50 1/50 5/50 | ||||
MAMMARY GLAND: FIBROADENOMA 24/49 32/50 36/50 36/50 | ||||
KIDNEY TUBULAR CELL: (SINGLE SECTIONS) ADENOMA 0/49 0/50 0/50 2/50 (SINGLE AND STEP SECTIONS) ADENOMA 0/49 0/50 0/50 4/50 | ||||
MAY HAVE BEEN RELATED: | LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA 1/49 0/50 0/50 3/50 | |||
URINARY BLADDER: TRANSITIONAL EPITHELIUM CARCINOMA 0/49 0/50 0/50 2/50 | ||||
NON-NEOPLASTIC LESIONS: | LUNG: ALVEOLAR EPITHELIUM HYPERPLASIA | |||
KIDNEY: INCREASED SEVERITY OF NEPHROPATHY | ||||
NASAL CAVITY: (OLFACTORY EPITHELIUM) ATROPHY; FIBROSIS; HYPERPLASIA; CHRONIC INFLAMMATION; METAPLASIA, NECROSIS | ||||
MM: CLEAR EVIDENCE | LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA 8/50 18/50 22/50 28/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 6/50 12/50 23/50 28/50 COMBINED 13/50 28/50 36/50 43/50 | |||
VASCULAR SYSTEM: HEMANGIOMA 0/50 1/50 2/50 2/50 OR HEMANGIOSARCOMA 3/50 13/50 22/50 19/50 COMBINED 3/50 14/50 23/50 21/50 | ||||
HARDERIAN GLAND: ADENOMA 2/50 5/50 8/50 10/50 OR CARCINOMA 0/50 0/50 2/50 2/50 COMBINED 2/50 5/50 10/50 12/50 | ||||
KIDNEY TUBULAR CELL: (SINGLE SECTIONS) ADENOMA 0/50 1/49 1/50 3/50 (SINGLE AND STEP SECTIONS) ADENOMA 0/50 2/49 3/50 9/50 | ||||
FORESTOMACH: SQUAMOUS CELL PAPILLOMA 1/50 0/50 2/50 4/50 | ||||
NON-NEOPLASTIC LESIONS: | LUNG: BRONCHIOLE HYPERPLASIA; HISTIOCYTIC CELL INFILTRATION | |||
FORESTOMACH: EPITHELIAL HYPERPLASIA | ||||
KIDNEY: RENAL TUBULE HYPERPLASIA | ||||
NASAL CAVITY: (OLFACTORY EPITHELIUM) ATROPHY; METAPLASIA; HYPERPLASIA | ||||
SPLEEN: HEMATOPOIETIC CELL PROLIFERATION | ||||
FM: CLEAR EVIDENCE | LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA 2/50 16/49 29/50 26/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 2/50 14/49 16/50 28/50 COMBINED 4/50 28/49 34/50 42/50 | |||
VASCULAR SYSTEM: HEMANGIOMA 0/50 0/50 2/50 3/50 OR HEMANGIOSARCOMA 4/50 6/50 17/50 5/50 COMBINED 4/50 6/50 18/50 8/50 | ||||
HARDERIAN GLAND: ADENOMA 1/50 3/50 3/50 8/50 OR CARCINOMA 1/50 2/50 0/50 1/50 COMBINED 2/50 5/50 3/50 9/50 | ||||
MAMMARY GLAND: CARCINOMA 3/50 4/50 7/50 12/50 | ||||
LIVER: ADENOMA 17/50 19/49 11/50 16/50 OR CARCINOMA 4/50 11/49 14/50 19/50 COMBINED 20/50 26/49 20/50 30/50 | ||||
SUBCUTANEOUS TISSUE: SARCOMA 0/50 11/50 11/50 18/50 | ||||
MESOTHELIUM (ABDOMINAL CAVITY/TUNICA VAGINALIS): SARCOMA 0/50 4/50 8/50 3/50 | ||||
ZYMBAL GLAND: CARCINOMA 0/50 0/50 0/50 3/50 | ||||
FORESTOMACH: SQUAMOUS CELL PAPILLOMA 0/50 0/50 0/50 4/50 | ||||
NON-NEOPLASTIC LESIONS: | LUNG: BRONCHIOLE HYPERPLASIA; HISTIOCYTIC CELL INFILTRATION | |||
FORESTOMACH: EPITHELIAL HYPERPLASIA | ||||
NASAL CAVITY: (OLFACTORY EPITHELIUM) ATROPHY; METAPLASIA; HYPERPLASIA | ||||
SPLEEN: HEMATOPOIETIC CELL PROLIFERATION |
Web page last updated on February 10, 2006
The National Institute of Environmental Health Sciences is one of the National Institutes of Health within the U.S. Department of Health and Human Services. The National Toxicology Program is headquartered on the NIEHS campus in Research Triangle Park, NC.